Back

Introduction - Oral anticoagulation in atrial fibrillation - From evidence-based medicine to daily clinical practice.

26 August 2018 (13:00 - 13:05)
Organised by:
Congress Presentation Part of: Oral anticoagulation in atrial fibrillation - From evidence-based medicine to daily clinical practice Treatment ESC Premium Access ESC Congress 2018

About the speaker

Photo
Doctor Jeffrey Weitz

Thrombosis & Atherosclerosis Research Institute (TaARI), Hamilton (Canada)

5 More presentations in this session

Presentation thumbnail
Safety of non-vitamin K antagonist oral anticoagulants - Considerations for management of atrial fibrillation patients .
Doctor C. Ruff (Boston, US)
Presentation thumbnail
Implication of the new EHRA practical guide for the treatment of atrial fibrillation patients.
Professor J. Steffel (Zurich, CH)
Presentation thumbnail
Complementing results from randomised trials: the value of international observational studies.
Professor P. Kirchhof (Hamburg, DE)
Presentation thumbnail
Panel discussion - Oral anticoagulation in atrial fibrillation - From evidence-based medicine to daily clinical practice
Doctor J. Weitz (Hamilton, CA)
Presentation thumbnail
Summary and close - Oral anticoagulation in atrial fibrillation - From evidence-based medicine to daily clinical practice.
Professor P. Kirchhof (Hamburg, DE)

Access the full session

Session thumbnail
Oral anticoagulation in atrial fibrillation - From evidence-based medicine to daily clinical practice

The Event

Event poster

ESC Congress 2018

26 August 2018 13:00 CET
You may be interested in
thumbnail
Congress Presentation
A new clinical decision support tool based on personalized evidence-based medicine improves outcomes of anticoagulation therapy in patients with atrial fibrillation: an analysis from the AF Registry
29 June 2021
thumbnail
Congress Presentation
Welcome and introduction
27 August 2023
thumbnail
Congress Presentation
Should we initiate oral anticoagulants for patients with atrial fibrillation staying well without oral anticoagulants for years?
28 August 2022
thumbnail
Congress Presentation
Edoxaban treatment in real-world practice is highly concordant with ESC atrial fibrillation guidelines: results from the non-interventional global ETNA-AF program
27 August 2021

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources